Pneumonia in HIV-Infected Patients

Etiology and Risk Factors

Streptococcus pneumoniae and Haemophilus influenzae are the most common bacterial causes of pneumonia in HIV-infected patients, while Pneumocystis jirovecii pneumonia (PCP) is the most common opportunistic pneumonia in advanced HIV disease, according to the Centers for Disease Control and Prevention (CDC) 1
Pseudomonas aeruginosa and Staphylococcus aureus have increased frequencies in HIV patients, and atypical pathogens like Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila species are also important considerations 1
Low CD4+ count, injection drug use, cigarette smoking, and advanced HIV disease are risk factors for pneumonia in HIV-infected patients, as noted by the CDC 1

HIV-infected patients with pneumonia may present with acute onset of symptoms, including fever, chills, rigors, chest pain, productive cough with purulent sputum, dyspnea, and focal consolidation on lung examination, as described by the CDC 1
Unilateral, focal, segmental, or lobar consolidation on chest radiograph and elevated WBC count with left shift are also common findings in HIV-infected patients with pneumonia, as reported by the CDC 1
Subacute onset with progressive dyspnea, non-productive cough, and fever may be seen in PCP, with normal or inspiratory crackles on lung examination and diffuse, bilateral interstitial infiltrates on chest radiograph, as noted by the CDC 1

Mycobacterium tuberculosis should always be considered in HIV patients with pneumonia, as they are at higher risk of tuberculosis compared to the general population, according to the CDC 1
A comprehensive workup, including chest radiograph or CT scan, is recommended for immunocompromised patients presenting with symptoms and cavitary pneumonia, to confirm cavitary lesions and assess extent of disease, with particular attention to patterns suggestive of specific etiologies, as suggested by the CDC 1
Pulse oximetry or arterial blood gas within 8 hours of presentation is essential to assess oxygen saturation, and tachypnea and decreased oxygen saturation indicate moderate-to-severe pneumonia requiring hospitalization, according to the CDC 1
Sputum collection for Gram stain and bacterial culture, acid-fast bacilli (AFB) smear and mycobacterial culture, fungal stain and culture, and PCP staining is crucial for identifying potential pathogens, as recommended by the CDC 1
Blood cultures, particularly important in immunocompromised patients due to higher incidence of bacteremia, should be collected before antibiotic administration, as suggested by the CDC 1
The Centers for Disease Control and Prevention recommends combination antibiotic therapy for bacterial pneumonia, with outpatients receiving an oral beta-lactam plus an oral macrolide, and never macrolide monotherapy due to increased risk of drug-resistant Streptococcus pneumoniae 1

The following treatment options are recommended:

Treatment Option	Recommendation
Antipneumococcal, antipseudomonal β-lactam + ciprofloxacin or levofloxacin	Infectious Diseases Society of America [2]
β-lactam + aminoglycoside and azithromycin	Centers for Disease Control and Prevention [1]
Aztreonam (for penicillin-allergic patients)	Centers for Disease Control and Prevention [1]

Antibiotic therapy should be directed specifically at the identified organism(s) once pathogen identification is confirmed through reliable microbiological methods, as recommended by the CDC 1
Empiric coverage should be de-escalated once culture results are available to prevent further resistance development, as recommended by the Infectious Diseases Society of America and the CDC 2, 1

The Centers for Disease Control and Prevention recommends pneumococcal vaccine for all HIV-infected patients 1
Annual inactivated influenza vaccine is recommended for all HIV-infected patients 1
Smoking cessation is recommended as smoking increases the risk of bacterial pneumonia and PCP 1
Reduction of substance use, including IDU and alcohol use, is recommended as it increases pneumonia risk 1
The CDC strongly recommends Pneumocystis jirovecii pneumonia (PCP) prophylaxis when CD4 counts are <200 cells/mL 3
The CDC recommends antiviral prophylaxis with acyclovir or valacyclovir for patients with history of herpes simplex or varicella zoster virus infection 3
The CDC suggests considering antifungal prophylaxis with fluconazole for severely immunosuppressed patients (CD4 <100 cells/mL) or those with anticipated prolonged neutropenia 3

Clinical response (reduction in fever, improvement in respiratory symptoms) typically observed within 48-72 hours after starting appropriate antibiotics, according to the CDC 1
Radiographic improvement may lag behind clinical improvement, as noted by the CDC 1
The CDC recommends considering adjunctive corticosteroids for severe pneumonia with progressive symptoms despite therapy 1
The CDC suggests switching from IV to oral therapy when patient is clinically stable (temperature <37.8°C, heart rate <100/min, respiratory rate <24/min, SBP >90 mmHg, O2 saturation >90%) 1
Drug interactions between antibiotics and antiretroviral medications should be monitored, particularly with rifamycins if TB treatment is initiated, as noted by the CDC 4
Immune reconstitution syndrome should be considered in patients who are starting or recently started on antiretroviral therapy, according to the CDC 4